EndometriosisFODMAPendoNCT07590895
Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms
A study testing FODMAP diet in people with Endometriosis, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
Trial summary
The main objective of the study is to assess whether a dietary regimen based on the principles of the FODMAP diet, compared with the current treatment programme which does not include specific dietary recommendations, can improve pain symptoms in patients with symptomatic endometriosis and intestinal symptoms (i.e. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Endometriosis
- What is being tested?
- FODMAP diet
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteItaly
- Study dates
- 1 Mar 2024to 15 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Age between 18 and 45 years
- BMI between 18.5 and 24.9,
- Surgical, clinical or instrumental diagnosis of endometriosis
- Presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, on estro-progestin or progestin treatment or in the absence of hormonal treatment
Who cannot join
- Associated conditions that may cause pelvic pain independent of the presence of endometriosis (e.g., pelvic varices and salpingitis outcomes)
- chronic inflammatory bowel disease (Crohn's disease or ulcerative rectocolitis).
- patients with obstructive uropathy, subocclusive intestinal stenosis
- complex adnexal masses or typical endometriomas greater than 5 cm in diameter.
- women who are obese (BMI ≥ 30) or underweight (BMI < 18)
- women on vegetarian-vegan dietary regimens,
- women with metabolic diseases that require specific dietary indications such as in the case of diabetes and celiac disease.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Milan, 20122
Giussy Barbara, MD, +393471753089, giussy.barbara@unimi.it
Dhouha Dridi, MD, +393429370961, dhouha.dridi@policlinico.mi.it
About this study
Official title: Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms: a Randomized Controlled Trial
The main objective of the study is to assess whether a dietary regimen based on the principles of the FODMAP diet, compared with the current treatment programme which does not include specific dietary recommendations, can improve pain symptoms in patients with symptomatic endometriosis and intestinal symptoms (i.e. bloating, nausea, constipation, diarrhoea and vomiting) attributable to irritable bowel syndrome, compared with a control group
Read the detailed description
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity, mostly, though not exclusively, in the pelvis. It is a chronic, estrogen-dependent inflammatory condition in which ectopic foci grow and proliferate under the action of estradiol, which plays a pro-inflammatory and anti-apoptotic role.
Pelvic pain represents the most typical manifestation of endometriosis. In particular, dysmenorrhea is the most frequent symptom.
In addition to typical gynecological symptoms, gastrointestinal symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) affect up to 90 percent of patients with endometriosis It has been reported how a diet low in oligosaccharides, disaccharides, monosaccharides, and fermentable polyols (FODMAP diet) is superior to other dietary treatments for the treatment of symptoms associated with irritable bowel syndrome.
Short-chain polysaccharides (FODMAPs) are found in a variety of fruits, vegetables and grains. FODMAPs are poorly absorbed in the gut, and are readily fermented by bacteria.
Their osmotic actions and gas production cause distention of the intestinal lumen inducing pain and bloating in patients with visceral hypersensitivity, with secondary effects on intestinal motility.
Although hormonal therapies represent the therapeutic cornerstone of endometriosis, we hypothesize that the FODMAP diet may represent a complementary and adjuvant approach for the treatment of abdominal/pelvic algic symptoms (and particularly bowel-type symptoms), resulting in significant improvement in the quality of life of affected women.
The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can improve algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome,
Eligible women will be selected among those attending the Endometriosis Clinic of the "L. Mangiagalli ", IRCCS Ca 'Granda Foundation and Ospedale Maggiore Policlinico, and will be randomized into two homogeneous groups ("intervention" and "control") (1:1): the intervention group will consist of women with symptomatic endometriosis and concomitant bowel symptoms under estro-progestin or progestin treatment, who will be asked to follow a dietary regimen based on the principles of the FODMAP diet; women in the control group will not be given specific instructions about the diet to follow.
Women will be randomized and assigned to two groups: 1) "FODMAP diet" (FD) group; 2) "usual diet" (UD) group. All patients participating in the study will undergo clinical and ultrasonographic evaluation at the beginning of the study, after 3 months and after 6 months. On these occasions, women will be routinely asked to complete some questionnaires, one on pain (a numerical rating scale, NRS), to the evaluation of gastrointestinal symptoms (NRS related to intestinal symptoms, such as abdominal bloating, nausea, constipation, diarrhea and vomiting), one on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological status (the Hospital Anxiety and Depression scale, HADS), one on sexual functioning (theFemale Sexual Function Index, FSFI) and one on the global impression of change (Patients' Global Impression of Change scale, PGIC). Women will also be asked to rate the degree of satisfaction with their treatment.
Patients randomized into the intervention group will participate in an initial meeting with the dietitian during which they will receive targeted nutritional counseling. They will be provided with the dietary pattern to follow. Follow-up of the diet will include telephone follow-up 6 to 8 weeks after the start of the study, at 3 months and at 6 months to assess dietary adherence.
- Conditions
- Endometriosis
- Being tested
- FODMAP diet
- Medical subject headings
- Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FODMAP dietBehavioural
Diet low in oligosaccharides, disaccharides, monosaccharides and fermentable polyols
| Study group | Role | What they receive |
|---|---|---|
| FODMAP diet group | Experimental | Patients randomized to the treatment arm were proposed to follow a FODMAP diet throughout the study period Receives: Behavioral: FODMAP diet |
| Usual diet group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of pain related syntomps in patients with bowel symptoms
The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can change algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, compared with a control group. The outcome will be measured trough Numerical Rating Scale (NRS) on dismenorrea, dyspareunia, non menstrual pelvic pain and dyschezia.
Measured: 6 months
Secondary outcomes (1)
Gastrointestinal syntomps, patient satisfaction, health-related quality of life, psychological conditions, patient's overall condition and anthropometric parameters
- Assessment of patient satisfaction during treatment, measured using a five-point Likert scale
- Assessment of gastrointestinal symptoms (abdominal bloating, nausea, constipation, diarrhea, and vomiting) using a numerical rating scale (NRS, 0 to 10)
- The impact on health-related quality of life assessed using the Short-Form Health Survey 12 (SF-12)
- The impact on sexual function using the Female Sexual Function Index (FSFI) questionnaire
- The impact on patients' psychological conditions using the HADS (Hospital Anxiety and Depression Scale)
- The patient's overall condition using the Patients' Global Impression of Change (PGIC) scale, a seven-point scale (greatly improved, much improved, slightly improved, unchanged, slightly worsened, muc
- Changes in anthropometric parameters through changes in BMI and impedance analysis of body composition
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start1 Mar 2024
- Primary completion15 Nov 2026 (estimated)
- Study completion15 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07590895
- Sponsor's protocol ID
- 3655_S_P
- Acronym
- FODMAPendo
- Status last verified
- Apr 2026
- First submitted
- 10 May 2024
- Last updated
- 15 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07590895
- Acronym / sponsor ID
- FODMAPendo / 3655_S_P
- Conditions
- Endometriosis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 15 Nov 2026 (estimated)
- Study completion
- 15 Dec 2026 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of the study is to assess whether a dietary regimen based on the principles of the FODMAP diet, compared with the current treatment programme which does not include specific dietary recommendations, can improve pain symptoms in patients with symptomatic endometriosis and intestinal symptoms (i.e. bloating, nausea, constipation, diarrhoea and vomiting) attributable to irritable bowel syndrome, compared with a control group
Detailed description
Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity, mostly, though not exclusively, in the pelvis. It is a chronic, estrogen-dependent inflammatory condition in which ectopic foci grow and proliferate under the action of estradiol, which plays a pro-inflammatory and anti-apoptotic role.
Pelvic pain represents the most typical manifestation of endometriosis. In particular, dysmenorrhea is the most frequent symptom.
In addition to typical gynecological symptoms, gastrointestinal symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) affect up to 90 percent of patients with endometriosis It has been reported how a diet low in oligosaccharides, disaccharides, monosaccharides, and fermentable polyols (FODMAP diet) is superior to other dietary treatments for the treatment of symptoms associated with irritable bowel syndrome.
Short-chain polysaccharides (FODMAPs) are found in a variety of fruits, vegetables and grains. FODMAPs are poorly absorbed in the gut, and are readily fermented by bacteria.
Their osmotic actions and gas production cause distention of the intestinal lumen inducing pain and bloating in patients with visceral hypersensitivity, with secondary effects on intestinal motility.
Although hormonal therapies represent the therapeutic cornerstone of endometriosis, we hypothesize that the FODMAP diet may represent a complementary and adjuvant approach for the treatment of abdominal/pelvic algic symptoms (and particularly bowel-type symptoms), resulting in significant improvement in the quality of life of affected women.
The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can improve algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome,
Eligible women will be selected among those attending the Endometriosis Clinic of the "L. Mangiagalli ", IRCCS Ca 'Granda Foundation and Ospedale Maggiore Policlinico, and will be randomized into two homogeneous groups ("intervention" and "control") (1:1): the intervention group will consist of women with symptomatic endometriosis and concomitant bowel symptoms under estro-progestin or progestin treatment, who will be asked to follow a dietary regimen based on the principles of the FODMAP diet; women in the control group will not be given specific instructions about the diet to follow.
Women will be randomized and assigned to two groups: 1) "FODMAP diet" (FD) group; 2) "usual diet" (UD) group. All patients participating in the study will undergo clinical and ultrasonographic evaluation at the beginning of the study, after 3 months and after 6 months. On these occasions, women will be routinely asked to complete some questionnaires, one on pain (a numerical rating scale, NRS), to the evaluation of gastrointestinal symptoms (NRS related to intestinal symptoms, such as abdominal bloating, nausea, constipation, diarrhea and vomiting), one on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological status (the Hospital Anxiety and Depression scale, HADS), one on sexual functioning (theFemale Sexual Function Index, FSFI) and one on the global impression of change (Patients' Global Impression of Change scale, PGIC). Women will also be asked to rate the degree of satisfaction with their treatment.
Patients randomized into the intervention group will participate in an initial meeting with the dietitian during which they will receive targeted nutritional counseling. They will be provided with the dietary pattern to follow. Follow-up of the diet will include telephone follow-up 6 to 8 weeks after the start of the study, at 3 months and at 6 months to assess dietary adherence.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| FODMAP diet group | Experimental | Behavioral: FODMAP dietPatients randomized to the treatment arm were proposed to follow a FODMAP diet throughout the study period |
| Usual diet group | No intervention | – |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age between 18 and 45 years
- BMI between 18.5 and 24.9,
- Surgical, clinical or instrumental diagnosis of endometriosis
- Presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, on estro-progestin or progestin treatment or in the absence of hormonal treatment
Key exclusion criteria (7 listed)
- Associated conditions that may cause pelvic pain independent of the presence of endometriosis (e.g., pelvic varices and salpingitis outcomes)
- chronic inflammatory bowel disease (Crohn's disease or ulcerative rectocolitis).
- patients with obstructive uropathy, subocclusive intestinal stenosis
- complex adnexal masses or typical endometriomas greater than 5 cm in diameter.
- women who are obese (BMI ≥ 30) or underweight (BMI < 18)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FODMAP dietDiet low in oligosaccharides, disaccharides, monosaccharides and fermentable polyols | Behavioural | FODMAP diet group |
Primary outcome
Change of pain related syntomps in patients with bowel symptoms
Time frame: 6 months
The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can change algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, compared with a control group. The outcome will be measured trough Numerical Rating Scale (NRS) on dismenorrea, dyspareunia, non menstrual pelvic pain and dyschezia.
1 secondary outcome
Gastrointestinal syntomps, patient satisfaction, health-related quality of life, psychological conditions, patient's overall condition and anthropometric parameters
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Individual participant dataSharing planned: No
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FODMAP diet in people with Endometriosis, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Giussy Barbara (+393471753089, giussy.barbara@policlinico.mi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of pain related syntomps in patients with bowel symptoms (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.